Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

about

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Item

http://www.wikidata.org/entity/Q48172397

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@en

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@nl

type

Item

label

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@en

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@nl

prefLabel

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@en

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@nl

P1476

Molecular monitoring of patien ...... ns for therapeutic adaptation.

@en

P2093

Audrey Bidet

http://www.w3.org/2001/XMLSchema#string

Claudine Chollet

http://www.w3.org/2001/XMLSchema#string

Denis Caillot

http://www.w3.org/2001/XMLSchema#string

Franck E Nicolini

http://www.w3.org/2001/XMLSchema#string

Francois-Xavier Mahon

http://www.w3.org/2001/XMLSchema#string

Martine Gardembas

http://www.w3.org/2001/XMLSchema#string

Philippe Genet

http://www.w3.org/2001/XMLSchema#string

Stéphanie Dulucq

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Discontinuation of TKI therapy and 'functional' cure for CML.

Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.

P304

148-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14748

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

Eric Lippert

Alain Delmer

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28485070

http://www.w3.org/2001/XMLSchema#string